Meni-D Disease Interactions, Meni-D


Buy Meni-D Disease Interactions, Meni-DCheap Meni-D Disease Interactions, Meni-DOrder Meni-D Disease Interactions, Meni-DMeni-D Disease Interactions, Meni-D Online No PrescriptionMeni-D Disease Interactions, Meni-D Online NowMeni-D Disease Interactions, Meni-D Without Prescriptions
Customer reviews
moles
Well done lad. Otvertelsya.
PayDevo4ka
Of course, I'm sorry, but you could not paint a little more.
Julismind
Willingly I accept. The question is interesting, I too will take part in the discussion.
Deeon
Spring!

Meni-D (meclizine) Disease Interactions

There are 4 disease interactions with Meni-D (meclizine):

Antihistamines (Includes Meni-D) ↔ Anticholinergic Effects

Severe Potential Hazard, High plausibility

Applies to: Gastrointestinal Obstruction, Glaucoma/Intraocular Hypertension, Urinary Retention

Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive. Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders. Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects. In contrast, the newer, relatively nonsedating antihistamines (e. g. cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.

References

"Product Information. Optimine (azatadine)." Schering Laboratories, Kenilworth, NJ.

"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.

"Product Information. Periactin (cyproheptadine)." Merck & Co, Inc, West Point, PA.

View all 20 references

Antihistamines (Includes Meni-D) ↔ Asthma/Copd

Moderate Potential Hazard, Moderate plausibility

Applies to: Asthma, Chronic Obstructive Pulmonary Disease

It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract. Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.

References

"Product Information. Temaril (trimeprazine)" Allergan Inc, Irvine, CA.

"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.

"Product Information. Periactin (cyproheptadine)." Merck & Co, Inc, West Point, PA.

View all 17 references

Antihistamines (Includes Meni-D) ↔ Cardiovascular

Moderate Potential Hazard, Moderate plausibility

Applies to: Cardiovascular Disease, Hyperthyroidism, Hypotension

Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities. Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported. Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.

References

"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.

"Product Information. Chlortrimeton (chlorpheniramine)." Schering-Plough, Liberty Corner, NJ.

"Product Information. Optimine (azatadine)." Schering Laboratories, Kenilworth, NJ.

View all 15 references

Antihistamines (Includes Meni-D) ↔ Renal/Liver Disease

Moderate Potential Hazard, High plausibility

Applies to: Liver Disease, Renal Dysfunction

Limited pharmacokinetic data are available for the older, first-generation antihistamines. Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine. Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation. Therapy with antihistamines should be administered cautiously in such patients. Lower initial dosages may be appropriate.

References

Paton DM, Webster DR "Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines)." Clin Pharmacokinet 10 (1985): 477-97

Rumore MM "Clinical pharmacokinetics of chlorpheniramine." Drug Intell Clin Pharm 18 (1984): 701-7

Blyden GT, Greenblatt DJ, Scavone JM, Shader RI "Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration." J Clin Pharmacol 26 (1986): 529-33

View all 15 references

Meni-D (meclizine) drug Interactions

There are 565 drug interactions with Meni-D (meclizine)

Meni-D (meclizine) alcohol/food Interactions